Biomarker-guided therapy for colorectal cancer: strength in complexity

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The number of molecularly stratified treatment options available to patients with colorectal cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide prognostication and treatment decision-making. The increase in both the number of biomarkers and their use has resulted in a progressively complex situation, evident both from the extensive interactions between biomarkers and from their sometimes complex associations with patient prognosis and treatment benefit. Current and emerging biomarkers also reflect the genomic complexity of CRC, and include a wide range of aberrations such as point mutations, amplifications, fusions and hypermutator phenotypes, in addition to global gene expression subtypes. In this Review, we provide an overview of current and emerging clinically relevant biomarkers and their role in the management of patients with CRC, illustrating the intricacies of biomarker interactions and the growing treatment opportunities created by the availability of comprehensive molecular profiling.

Original languageEnglish (US)
Pages (from-to)11-32
Number of pages22
JournalNature Reviews Clinical Oncology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

Colorectal Neoplasms
Biomarkers
Therapeutics
Point Mutation
Decision Making
Phenotype
Gene Expression

ASJC Scopus subject areas

  • Oncology

Cite this

Biomarker-guided therapy for colorectal cancer : strength in complexity. / Sveen, Anita; Kopetz, Scott; Lothe, Ragnhild A.

In: Nature Reviews Clinical Oncology, Vol. 17, No. 1, 01.01.2020, p. 11-32.

Research output: Contribution to journalReview article

@article{0cae890289664314bbaca26cc9f7c7da,
title = "Biomarker-guided therapy for colorectal cancer: strength in complexity",
abstract = "The number of molecularly stratified treatment options available to patients with colorectal cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide prognostication and treatment decision-making. The increase in both the number of biomarkers and their use has resulted in a progressively complex situation, evident both from the extensive interactions between biomarkers and from their sometimes complex associations with patient prognosis and treatment benefit. Current and emerging biomarkers also reflect the genomic complexity of CRC, and include a wide range of aberrations such as point mutations, amplifications, fusions and hypermutator phenotypes, in addition to global gene expression subtypes. In this Review, we provide an overview of current and emerging clinically relevant biomarkers and their role in the management of patients with CRC, illustrating the intricacies of biomarker interactions and the growing treatment opportunities created by the availability of comprehensive molecular profiling.",
author = "Anita Sveen and Scott Kopetz and Lothe, {Ragnhild A.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1038/s41571-019-0241-1",
language = "English (US)",
volume = "17",
pages = "11--32",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Biomarker-guided therapy for colorectal cancer

T2 - strength in complexity

AU - Sveen, Anita

AU - Kopetz, Scott

AU - Lothe, Ragnhild A.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The number of molecularly stratified treatment options available to patients with colorectal cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide prognostication and treatment decision-making. The increase in both the number of biomarkers and their use has resulted in a progressively complex situation, evident both from the extensive interactions between biomarkers and from their sometimes complex associations with patient prognosis and treatment benefit. Current and emerging biomarkers also reflect the genomic complexity of CRC, and include a wide range of aberrations such as point mutations, amplifications, fusions and hypermutator phenotypes, in addition to global gene expression subtypes. In this Review, we provide an overview of current and emerging clinically relevant biomarkers and their role in the management of patients with CRC, illustrating the intricacies of biomarker interactions and the growing treatment opportunities created by the availability of comprehensive molecular profiling.

AB - The number of molecularly stratified treatment options available to patients with colorectal cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide prognostication and treatment decision-making. The increase in both the number of biomarkers and their use has resulted in a progressively complex situation, evident both from the extensive interactions between biomarkers and from their sometimes complex associations with patient prognosis and treatment benefit. Current and emerging biomarkers also reflect the genomic complexity of CRC, and include a wide range of aberrations such as point mutations, amplifications, fusions and hypermutator phenotypes, in addition to global gene expression subtypes. In this Review, we provide an overview of current and emerging clinically relevant biomarkers and their role in the management of patients with CRC, illustrating the intricacies of biomarker interactions and the growing treatment opportunities created by the availability of comprehensive molecular profiling.

UR - http://www.scopus.com/inward/record.url?scp=85068902954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068902954&partnerID=8YFLogxK

U2 - 10.1038/s41571-019-0241-1

DO - 10.1038/s41571-019-0241-1

M3 - Review article

AN - SCOPUS:85068902954

VL - 17

SP - 11

EP - 32

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 1

ER -